Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients

BACKGROUND: Enzyme replacement therapy is currently the only approved therapy for Fabry disease. From June 2009 on, viral contamination of Genzyme's production facility resulted in a worldwide shortage of agalsidase beta leading to involuntary dose reductions (approved dose 1 mg/kg/eow, reduced...

Descripción completa

Detalles Bibliográficos
Autores principales: Smid, Bouwien E, Rombach, Saskia M, Aerts, Johannes MFG, Kuiper, Symen, Mirzaian, Mina, Overkleeft, Hermen S, Poorthuis, Ben JHM, Hollak, Carla EM, Groener, Johanna EM, Linthorst, Gabor E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3219561/
https://www.ncbi.nlm.nih.gov/pubmed/22041095
http://dx.doi.org/10.1186/1750-1172-6-69

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3219561/
https://www.ncbi.nlm.nih.gov/pubmed/22041095
http://dx.doi.org/10.1186/1750-1172-6-69

Ejemplares similares